Tian'an Pharmaceutical Co. Ltd.

06/17/2026 | Press release | Distributed by Public on 06/17/2026 07:23

Partnership And Significant Shareholder

Partnership And Significant Shareholder
Officer/Director/Affiliate Stock Transactions
OTC Disclosure & News Service | 06/17/2026

China Blue Gold Digital Holdings Group Co Ltd ("Blue Gold Digital") has acquired a 21% shareholding in Tian'an Pharmaceutical Co Ltd ("TNPH" or the "Company") from Jiudu Tian'an Holding International Group Co. Ltd.

Mr Wenjie He, President of Blue Gold Shangshu Yun (Guangzhou) Technology Co. Ltd, will join TNPH's Board of Directors.

Blue Gold Digital and TNPH management teams intend to work together to help expand Blue Gold Digital's operations into international markets, including Southeast Asian countries such as Malaysia, Vietnam, and Thailand, to help sell well-known brands and products, including Luo Han Guo (monk fruit) products, into international markets.

They will also work together to consult on capital mergers and acquisitions and asset restructuring for Chinese enterprises, and in asset management services.

Your attention is drawn to the Forward Looking Statement notice below, which is an integral part of this news release, and should be read in conjunction with this news release.

This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management's current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties, Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

Tian'an Pharmaceutical Co. Ltd. published this content on June 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 17, 2026 at 13:23 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]